Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2011-01-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 10 pages 62.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2010'. It contains detailed operational updates, licensing and IP activities, research and development progress, corporate matters, and a consolidated statement of cash flows for the quarter and year to date. The presence of substantive financial data such as cash flows, revenues, and expenses confirms it is a comprehensive financial report for a period shorter than a full fiscal year. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The quarterly period ending 31 December 2010 and the detailed financial and operational information align with the definition of an Interim / Quarterly Report (IR). Therefore, the correct classification is IR with high confidence. Q2 2011
2011-01-27 English
Ceasing to be a substantial holder 1 page 32.6KB
Regulatory Filings
2011-01-20 English
Second patent infringement law suit filed 2 pages 45.9KB
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated January 20, 2011, reporting the filing of a second patent infringement lawsuit in the USA by Genetic Technologies Limited. It discusses legal actions, settlements, and ongoing negotiations related to patent infringement. There are no financial statements, earnings data, or management discussion of financial results. The content focuses on legal proceedings and updates on litigation matters. Therefore, the document fits best under the category of Legal Proceedings Report (LTR). The document length is 4012 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is LTR with high confidence.
2011-01-19 English
Settlement of dispute with Sunrise Medical 1 page 3
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated January 17, 2011, reporting the execution of a Settlement Agreement between Genetic Technologies Limited and Sunrise Medical Laboratories. It references a patent infringement lawsuit and settlement discussions but does not contain any financial statements, detailed financial data, or comprehensive report content. The document is relatively short (2759 characters) and serves as a disclosure of a legal settlement rather than a full legal proceedings report or financial report. Given the nature of the content—an update on a legal settlement—and the absence of detailed legal case documentation or financial data, the most appropriate classification is Legal Proceedings Report (LTR).
2011-01-16 English
Investor presentation 30 pages 2.1MB
Investor Presentation Classification · 95% confidence The document is titled as an ASX Announcement dated January 10, 2011, and it contains a detailed investor presentation by the CEO of Genetic Technologies Limited. The content includes business strategy, product launch plans, market opportunity, validation studies, sales and marketing deployment, licensing and patent assertion programs, regulatory and reimbursement strategies, key opinion leaders, infrastructure, competitors, oncology focus, and financial trends. The document is a comprehensive presentation aimed at investors, focusing on financials, strategy, and market position. It is not a full annual or quarterly report, audit report, earnings release, or regulatory filing. It is not a brief factsheet or a voting result announcement. The length is substantial (15,000 characters), and it is clearly a presentation document. Therefore, the most appropriate classification is Investor Presentation (IP).
2011-01-09 English
Response to ASX Query 4 pages 86.5KB
Regulatory Filings
2011-01-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.